دورية أكاديمية
أعرض في EDS

Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries.

التفاصيل البيبلوغرافية
العنوان: Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries.
المؤلفون: Altin M; Eli Lilly Neuroscience, Eli Lilly & Company Turkey, Lilly İlaç Ticaret Ltd. Şti. Kuşbakişi Caddesi, Rainbow Plaza No:4 Kat:3,34662; Altunizade, İstanbul, Turkey;, El-Shafei AA; Eli Lilly, 1229 El Sheikh Aly Gad El Haq St., Floor 6 Sheraton Bldgs, Heliopolis, Cairo, Egypt;, Yu M; Eli Lilly Canada, 3650 Danforth Ave, Toronto, Ontario, Canada;, Desaiah D; Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN;, Treuer T; Neuroscience Research, Eli Lilly and Company, 1075 Budapest, Madách u. 13-14, Hungary;, Zavadenko N; Dept. of Neurology, Neurosurgery and Medical Genetics of Pediatric Faculty, Russian State Medical University, Ostrovityanova Str. 1, Moscow, Russian Federation;, Gao HY; Dept. of Psychological Medicine, Children's Hospital of Fudan University, 399 Wanyuan Lu, Shanghai, China.
المصدر: Drugs in context [Drugs Context] 2013 Sep 13; Vol. 2013, pp. 212260. Date of Electronic Publication: 2013 Sep 13 (Print Publication: 2013).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Bioexcel Publishing Ltd Country of Publication: England NLM ID: 101262187 Publication Model: eCollection Cited Medium: Print ISSN: 1745-1981 (Print) Linking ISSN: 17404398 NLM ISO Abbreviation: Drugs Context Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2016- : London : Bioexcel Publishing Ltd.
Original Publication: Long Hanborough, Oxon : CSF Medical Communications, c2005-
مستخلص: Objective: Functional outcomes were measured over a 12-month period in children and adolescents with attention deficit hyperactivity disorder (ADHD) after they received monotherapy.
Design: Prospective, observational, noninterventional study.
Setting: Conducted in six non-Western countries.
Participants: Outpatients 6 to 17 years of age with a verified diagnosis of ADHD in accordance with the Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR), together with their physicians, decided to initiate or switch treatment for ADHD. Patients were prescribed pharmacological monotherapy: methylphenidate (n=221), nootropic agents (n=91), or atomoxetine (n=234).
Measurements: Patients were followed for changes in their functional status and quality of life, which were assessed with the Child Health and Illness Profile-Child Edition (CHIP-CE) Achievement domain.
Results: At the end of the study, a mean improvement on the CHIP-CE Achievement domain score was observed for all countries and therapies except in Taiwan, where patients received atomoxetine, and in Lebanon, where patients received methylphenidate. No patient experienced a serious adverse event during the study. Four patients discontinued due to a treatment-emergent adverse event.
Conclusion: After 12 months of treatment, clinical and functional outcomes were improved in children and adolescents from non-Western countries who initiated and remained on their prescribed pharmacological monotherapy.
References: Curr Med Res Opin. 2007 Feb;23(2):379-94. (PMID: 17288692)
J Atten Disord. 2012 Jan;16(1):44-59. (PMID: 20858785)
Eur Child Adolesc Psychiatry. 2006 Dec;15 Suppl 1:I63-71. (PMID: 17177018)
Neuropsychopharmacology. 2002 Nov;27(5):699-711. (PMID: 12431845)
Am J Psychiatry. 2008 Jun;165(6):721-30. (PMID: 18281409)
Eur Child Adolesc Psychiatry. 2010 Jan;19(1):57-66. (PMID: 19568826)
J Psychopharmacol. 2012 Jun;26(6):753-65. (PMID: 21948938)
J Child Adolesc Psychopharmacol. 2001 Fall;11(3):251-65. (PMID: 11642475)
J Atten Disord. 2008 Mar;11(5):538-45. (PMID: 18192617)
Child Adolesc Psychiatry Ment Health. 2008 Jul 03;2(1):15. (PMID: 18598351)
Am J Psychiatry. 2002 Nov;159(11):1896-901. (PMID: 12411225)
J Child Adolesc Psychopharmacol. 2009 Aug;19(4):363-76. (PMID: 19702488)
Med Care. 2004 Mar;42(3):221-31. (PMID: 15076821)
Biol Psychiatry. 2001 Oct 15;50(8):586-92. (PMID: 11690593)
Pediatrics. 2004 Jul;114(1):e1-8. (PMID: 15231966)
J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):241-9. (PMID: 11211374)
Vital Health Stat 10. 2002 May;(206):1-12. (PMID: 15789507)
East Asian Arch Psychiatry. 2010 Jun;20(2):76-86. (PMID: 22351813)
JAMA. 1998 Apr 8;279(14):1100-7. (PMID: 9546570)
Pediatrics. 2011 Nov;128(5):1007-22. (PMID: 22003063)
Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I36-42. (PMID: 15322955)
Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(10 Pt 1):28-32. (PMID: 22500309)
Int J Psychiatry Clin Pract. 2010 Jun;14(2):116-26. (PMID: 24922471)
CNS Drugs. 2010 Feb;24(2):99-117. (PMID: 20088618)
Arch Gen Psychiatry. 1999 Dec;56(12):1073-86. (PMID: 10591283)
J Am Acad Child Adolesc Psychiatry. 2001 Nov;40(11):1285-92. (PMID: 11699802)
Child Adolesc Psychiatry Ment Health. 2010 Dec 06;4:30. (PMID: 21134277)
J Am Acad Child Adolesc Psychiatry. 2010 Apr;49(4):345-55. (PMID: 20410727)
Med Care. 2004 Mar;42(3):210-20. (PMID: 15076820)
Zh Nevrol Psikhiatr Im S S Korsakova. 2004;104(3):32-7. (PMID: 15071842)
Eur Child Adolesc Psychiatry. 2004 Dec;13(6):354-61. (PMID: 15619047)
Pediatrics. 2008 Feb;121(2):e314-20. (PMID: 18245404)
Pediatrics. 2001 Nov;108(5):E83. (PMID: 11694667)
J Am Acad Child Adolesc Psychiatry. 2001 Jun;40(6):704-10. (PMID: 11392349)
J Clin Child Adolesc Psychol. 2002 Dec;31(4):443-52. (PMID: 12402564)
فهرسة مساهمة: Keywords: adolescent; adverse drug events; atomoxetine; attention deficit hyperactivity disorder; central nervous system stimulants; child; nootropic agents; treatment outcome
تواريخ الأحداث: Date Created: 20140117 Date Completed: 20140116 Latest Revision: 20211021
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC3884848
DOI: 10.7573/dic.212260
PMID: 24432046
قاعدة البيانات: MEDLINE
الوصف
تدمد:1745-1981
DOI:10.7573/dic.212260